Klacid-SR (Clarithromycin) is a semisynthetic macrolide antibiotic prolonged action, used to treat various bacterial infections, with bacteriostatic action. Klacid-SR (Clarithromycin) binds to the 50s-subunit of the bacterial ribosome, causing suppression of bacterial protein synthesis. Klacid-SR (Clarithromycin) acts mainly bacteriostatic, as well as bactericidal.
Klacid-SR (Clarithromycin) inhibits protein synthesis in a microbial cell and is active against:
- gram-positive aerobic microorganisms - Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumonia, Listeria monocytogenes
- aerobic gram-negative microorganisms - Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella (Branhamella) catarrhalis, Neisseria gonorrhoea, Legionella pneumophila, Helicobacter pylori
- advantageously intracellular microorganisms - Mycoplasma pneumonia, Chlamydia pneumonia (TWAR), Mycobacterium leprae, Mycobacterium kansaii, Mycobacterium chelonae, Mycobacterium fortitum, Mycobacterium avium complex (MAC), Mycobacterium intracellulare.
In vitro, Klacid-SR (Clarithromycin) is active against most strains of the following microorganisms:
- aerobic gram-positive microorganisms - Streptococcus agalactiae, Streptococci (groups C, F, G), Streptococcus viridans
- aerobic gram-negative microorganisms - Bordetella pertussis, Pasteurella multocida, Campylobacter jejuni
- anaerobic gram-positive microorganisms - Clostridium perfringens, Peptococcus niger, Propionibacterium acnes
- anaerobic gram-negative microorganisms - Bacteroides melaninogenicus
- spirochete - Borrelia burgdorferi, Treponema pallidum.
Klacid-SR (Clarithromycin) is well absorbed from the gastrointestinal tract. Eating slows down the absorption of Klacid (Clarithromycin), but does not affect the bioavailability of the active substance.
Approximately 20% of Klacid-SR (Clarithromycin) is immediately metabolized to form the main metabolite of 14-hydrochlorithromycin.
- lower respiratory tract infections (bronchitis, pneumonia)
- upper respiratory tract infections (pharyngitis, sinusitis)
- infections of the skin and soft tissues (folliculitis, cellulitis, erysipelas)
- common mycobacterial infections caused by Mycobacterium avium and Mycobacterium intracellulare
- localized mycobacterial infections caused by Mycobacterium chelonae, Mycobacterium fortuitum and Mycobacterium kansasii
- Helicobacter pylori eradication and a decrease in the frequency of relapse of a duodenal ulcer
- Lyme disease
- prevention of the spread of infection due to the Mycobacterium avium complex (MAC) complex in HIV-infected patients with a CD4 lymphocyte count (T-helper lymphocytes) of not more than 100 in 1 mm3
- odontogenic infections.
- severe liver dysfunction
- severe renal impairment (CC <30 ml / min)
- simultaneous use with astemizole, cisapride, pimozide, terfenadine, ergotamine, dihydroergotamine
- pregnancy, lactation (breastfeeding)
- children's age up to 3 years (when using tablets)
- hypersensitivity to antibiotics of the macrolide group.
Klacid-SR (Clarithromycin) should be used with caution in patients with impaired liver and kidney function.
CAS Number: 81103-11-9
Package: 14 tabs 500 mg.